%0 Journal Article
%T Optimal management of high bleeding risk patients undergoing percutaneous coronary interventions: Where do we stand?
%A Dimitriadis K
%A Pyrpyris N
%A Iliakis P
%A Kanatas P
%A Theofilis P
%A Sakalidis A
%A Apostolos A
%A Tsioufis P
%A Papanikolaou A
%A Aznaouridis K
%A Aggeli K
%A Tsioufis K
%J J Cardiol
%V 0
%N 0
%D 2024 Aug 10
%M 39134301
%F 2.974
%R 10.1016/j.jjcc.2024.08.002
%X Percutaneous coronary interventions (PCI) are the mainstay of treating obstructive coronary artery disease. However, procedural planning and individualization of the procedure is necessary for different patient phenotypes to optimize outcomes. Specifically, post-PCI pharmacotherapy with antiplatelets complicates the management of patients at high bleeding risk due to comorbidities, such as atrial fibrillation. Aiming to limit post-procedural adverse events and reduce the procedure-related bleeding risk, several novel technologies and hypotheses have been tested in clinical practice. Such frontiers include limiting the duration of dual antiplatelet therapy or even prescribing single regimens, using drug-coated balloons for performing the intervention and the effect of imaging-guided PCI in optimizing stent expansion. Furthermore, specific instruction in different patient phenotypes, such as atrial fibrillation and chronic kidney disease, are emerging, as despite both pathologies being considered at high bleeding risk, one size does not fit all. Thus, our review will provide all the recent updates on the field as well as algorithms and expert opinions on how to manage this, particularly common, phenotype of patient.